BeOne Medicines price target raised to $330 from $313 at Morgan Stanley

finance.yahoo.com/news/beone-medicines-price-target-raised-123543358.html

In This Article:
Morgan Stanley raised the firm’s price target on BeOne Medicines (ONC) to $330 from $313 and keeps an Overweight rating on the shares following the R&D day that highlighted the company’s pipeline programs. Management is targeting a 2026 approval for Sonrotoclax and 2027…

This story appeared on finance.yahoo.com, 2025-06-28 12:35:43.
The Entire Business World on a Single Page. Free to Use →